Literature DB >> 28105267

Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2016        PMID： 28105267      PMCID： PMC5238480          DOI： 10.1021/acsmedchemlett.6b00514

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  PDE2 inhibition: potential for the treatment of cognitive disorders.

Authors:  Laurent Gomez; J Guy Breitenbucher
Journal:  Bioorg Med Chem Lett       Date:  2013-10-24       Impact factor: 2.823

Review 3.  Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction.

Authors:  Marlies Van Duinen; Olga A H Reneerkens; Lena Lambrecht; Anke Sambeth; Bart P F Rutten; Jim Van Os; Arjan Blokland; Jos Prickaerts
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116
  3 in total
  1 in total

Review 1.  Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development.

Authors:  Stuart P McCluskey; Christophe Plisson; Eugenii A Rabiner; Oliver Howes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-21       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.